Skip to main content
Premium Trial:

Request an Annual Quote

First US Patent for Athersys on Expression System

NEW YORK, April 23-The United States patent office has granted functional genomics firm Athersys its first patent for its gene expression system.

 

The patent covers activation and production of secreted proteins and cell surface proteins in Athersys' "Random Activation of Gene Expression" technology. It was issued on March 26, 2002, but the company announced the patent today.

 

The RAGE system allows researchers to express proteins without first cloning and isolating genes, by integrating specialized activation sequences into the genome of the host cell.

 

The company has established four major collaborations with pharmaceutical partners based on the technology.

 

According to Athersys, it has filed 17 other patents on this technique, and expects additional approvals in the next six months.

 

Athersys is using its library of secreted proteins to identify factors that regulate cellular function, growth, and development, among other projects, said company chairman, president, and CEO Gil Van Bokkelen in a statement.

 

Athersys is based in Cleveland, Ohio.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.